Bis-acridone chemotherapeutic derivatives
    2.
    发明授权
    Bis-acridone chemotherapeutic derivatives 失效
    双吖啶酮化疗衍生物

    公开(公告)号:US5508289A

    公开(公告)日:1996-04-16

    申请号:US213315

    申请日:1994-03-14

    CPC分类号: A61K49/0026 C07D219/08

    摘要: The present invention provides an anticancer compound having the structure: ##STR1## wherein R is --H, --CH.sub.3, or --C.sub.2 H.sub.5 ; R1 and R2 are independently --H, --OH, --NH.sub.2, --OCH.sub.3, --C(CH.sub.3).sub.3, or a halogen atom; n is 2 to 6; X and X' are independently --N or --NO.sub.2 ; Y and Y' are independently --N, --CH, or --H; and the double-slash represents a double bond or no bond; such that when X or X' is --N, Y or Y' is --CH or --N, and the double-slash is a double bond, and when X or X' is --NO.sub.2, Y or Y' is --H, and the double-slash is no bond. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier.

    摘要翻译: 本发明提供具有以下结构的抗癌化合物:其中R为-H,-CH 3或-C 2 H 5; R 1和R 2独立地是-H,-OH,-NH 2,-OCH 3,-C(CH 3)3或卤素原子; n为2〜6; X和X'独立地是-N或-NO 2; Y和Y'独立地是-N,-CH或-H; 双斜杠代表双键或无键; 使得当X或X'为-N时,Y或Y'为-CH或-N,双斜线为双键,当X或X'为-NO 2时,Y或Y'为-H, 而双斜杠是没有纽带的。 本发明还提供包含上述化合物和药学上可接受的载体的药物组合物。

    Antineoplastic modified imidazoacridines
    8.
    发明授权
    Antineoplastic modified imidazoacridines 失效
    抗生素改性咪达唑仑

    公开(公告)号:US5231100A

    公开(公告)日:1993-07-27

    申请号:US760694

    申请日:1991-09-16

    CPC分类号: C07D471/06

    摘要: Compounds of formula I: ##STR1## in which: R represents: --OH or --OR', wherein R' represents C.sub.1 -C.sub.6 alkyl,R.sub.1.sup.a and R.sub.1.sup.b, which may be identical or different, represent hydrogen or C.sub.1 -C.sub.6 alkyl, unsubstituted or substituted by a hydroxyl, an amino, a N'-alkylamino or a N',N'-dialkylamino group, such N'-alkyl groups containing 1-4 carbon atoms,n is 2-5 andR.sub.2 represents hydrogen, or straight chain C.sub.1 -C.sub.4 alkyl, in the form of a free base or a pharmaceutically acceptable acid addition salt are useful in antineoplastic treatment and prophylaxis, especially of leukemias.